EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| Formula | C23H18ClN3O |
| Net Charge | 0 |
| Average Mass | 387.870 |
| Monoisotopic Mass | 387.11384 |
| SMILES | CC1=Nc2ccccc2N=C(NC(=O)c2ccccc2)C1c1ccc(Cl)cc1 |
| InChI | InChI=1S/C23H18ClN3O/c1-15-21(16-11-13-18(24)14-12-16)22(26-20-10-6-5-9-19(20)25-15)27-23(28)17-7-3-2-4-8-17/h2-14,21H,1H3,(H,26,27,28) |
| InChIKey | WQYDOUFKOYQSSS-UHFFFAOYSA-N |
| Roles Classification |
|---|
| Biological Role: | GABA modulator A substance that does not act as agonist or antagonist but does affect the gamma-aminobutyric acid receptor-ionophore complex. GABA-A receptors appear to have at least three allosteric sites at which modulators act: a site at which benzodiazepines act by increasing the opening frequency of gamma-aminobutyric acid-activated chloride channels; a site at which barbiturates act to prolong the duration of channel opening; and a site at which some steroids may act. |
| Application: | GABA modulator A substance that does not act as agonist or antagonist but does affect the gamma-aminobutyric acid receptor-ionophore complex. GABA-A receptors appear to have at least three allosteric sites at which modulators act: a site at which benzodiazepines act by increasing the opening frequency of gamma-aminobutyric acid-activated chloride channels; a site at which barbiturates act to prolong the duration of channel opening; and a site at which some steroids may act. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| N-[3-(4-chlorophenyl)-2-methyl-3H-1,5-benzodiazepin-4-yl]benzamide (CHEBI:115662) is a benzodiazepine (CHEBI:22720) |
| Manual Xrefs | Databases |
|---|---|
| LSM-27119 | LINCS |